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Abstract
We have previously reported that artemin (ARTN) stimulates the oncogenicity and invasiveness of endometrial car-
cinoma cells. Herein, we demonstrate that ARTN modulates the sensitivity of endometrial carcinoma cells to agents
used to treat late-stage endometrial carcinoma. Forced expression of ARTN in endometrial carcinoma cells de-
creased sensitivity to doxorubicin and paclitaxel. Accordingly, depletion of ARTN by small interfering RNA or func-
tional inhibition of ARTN with antibodies significantly increased sensitivity of endometrial carcinoma cells to
doxorubicin and paclitaxel. Forced expression of ARTN in endometrial carcinoma cells abrogated doxorubicin-
induced G2-M arrest and paclitaxel-induced apoptosis. ARTN increased CD24 expression in endometrial carcinoma
cells by transcriptional up-regulation, and CD24 was partially correlated to ARTN expression in endometrial carci-
noma. Forced expression of CD24 in endometrial carcinoma cells stimulated cell proliferation and oncogenicity,
enhanced cell invasion, and decreased sensitivity to doxorubicin and paclitaxel. Depletion of CD24 in endometrial
carcinoma cells abrogated ARTN-stimulated resistance to doxorubicin and paclitaxel. ARTN-stimulated resistance
to doxorubicin and paclitaxel in endometrial carcinoma cells is therefore mediated by the specific regulation of
CD24. Functional inhibition of ARTN may therefore be considered as an adjuvant therapeutic approach to improve
the response of endometrial carcinoma to specific chemotherapeutic agents.
Translational Oncology (2010) 3, 218–229
Introduction
Endometrial carcinoma (EC) is the most common malignancy of the
female reproductive tract. Most cases diagnosed at an early stage (I/II)
of the disease are treated with hysterectomy followed by radiation and
exhibit a good prognosis [1]. Chemotherapy followed by hysterectomy
is the only option for the treatment of late-stage and recurrent EC
[1]. However, chemotherapy is not sufficient to produce long-lasting tu-
mor regression in patients with late-stage (III/IV) and recurrent EC [1].
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Patientswith late-stageEC invariably exhibit amultidrug-resistant pheno-
type and experience a recurrence after therapy, with a median survival
time less than 12 months [1]. Poor survival of late-stage and recurrent
EC patients, particularly with an aggressive histological subtype, necessi-
tates the development of new therapeutic modalities for advanced-stage
and recurrent EC.
Artemin (ARTN) is a neurotrophic factor belonging to the glial cell–
derived neurotrophic factor family of ligands. An elevated expression
of ARTN has been observed in pancreatic, mammary, and ECs [2–4].
In mammary carcinoma, an elevated expression of ARTN predicted re-
sidual disease after chemotherapy, metastases, relapse, and death [4]. An
elevated expression of ARTN in EC is associated with high tumor grade
and myometrial invasion [2]. Functionally, the expression of ARTN
promoted oncogenicity, tumor growth, and invasion of both mammary
and EC cells [2,4].
CD24 is a small, heavily glycosylated protein with frequently in-
creased expression in a wide range of human carcinomas including
EC [5,6]. Elevated CD24 expression is a prognostic indicator of poor
survival in non–small cell lung [7], prostate [6], mammary [8], and
ovarian carcinomas [9]. In addition, CD24 has been repeatedly identi-
fied in gene expression profiling screens used to identify genes whose
expression correlates with oncogenesis and tumor development [10–
12]. CD24 has been reported to support the acquisition of multiple
cellular properties associated with tumor development and metastasis
[13]. Concordantly, transient down-regulation of CD24 expression in
human carcinoma cell lines (mammary, urothelial, and prostate) resulted
in growth inhibition and reduced clonogenicity and cell migration [14].
Similarly, functional inhibition of CD24 using small interfering RNA
(siRNA) or a monoclonal antibody (mAb) abrogated cell growth of
colorectal and pancreatic carcinoma cells in vitro and in vivo [15].
We therefore speculated that ARTN expression may modulate sen-
sitivity to chemotherapeutics used in EC. In this article, we determined
the effects of ARTN expression on the sensitivity of EC cells toward
doxorubicin and paclitaxel, the therapeutic agents used to treat late-
stage EC [16]. Antibodies to ARTN increased the sensitivity of EC cells
to doxorubicin and paclitaxel, indicating a potential therapeutic strategy
to increase the efficacy of chemotherapeutic agents in EC.
Materials and Methods
Cell Culture and Reagents
The human EC cell lines RL95-2 and AN3 were obtained from the
American Type Culture Collection (ATCC, Rockville, MD) and were
cultured as per ATCCpropagation instructions. Stable cell lines were gen-
erated as previously described [17]. Doxorubicin and paclitaxel were
purchased from Sigma-Aldrich (Auckland, New Zealand). Bioassays with
ARTN polyclonal chicken immunoglobulin (IgY) were performed as
previously described [4].
Plasmids and Luciferase Assay
ARTN expression vector and siRNA plasmid constructs were previ-
ously described [4]. The CD24 expression vector was as a generous
gift from Drs H. Kataoka and T. Fukushima (University of Miyazaki,
Japan) [18]. Short-hairpin RNA (shRNA) for CD24 was obtained from
Clontech Laboratories, Inc (Mountain View, CA). The CD24-luciferase
reporter plasmid was a generous gift from Dr C. Sakanaka (Genentech,
Inc, San Francisco, CA) [19]. EC cells were transfected in a 12-well plate
at 5 × 105 cells per well using FuGENE6 (Roche Molecular Biochem-
icals, Indianapolis, IN) transfection reagent. Transfections were carried
out in triplicate using 1 μg of the appropriate CD24 promoter luciferase
reporter plasmid and empty vector per transfection along with 0.2 μg of
pSV-β-galactosidase expression plasmid as control for transfection effi-
ciency. Luciferase activities were assayed 48 hours after transfection using
the dual Luciferase Assay System (Promega Corp, Madison, WI) as pre-
viously described [19].
Reverse Transcription–Polymerase Chain Reaction and
Quantitative Polymerase Chain Reaction
Total RNA was isolated from cells (cultured in 10% fetal bovine
serum) using TRIzol Plus RNA Purification system at 1 ml/10 cm2
according to the manufacturer’s instructions (Invitrogen). RNA sam-
ples were further treated with DNase I for 30 minutes at 37°C. Total
RNA was converted to complementary DNA (cDNA) by using Super-
Script III First-Strand Synthesis SuperMix for quantitative polymerase
chain reaction (qPCR) according to the manufacturer’s instructions
(Invitrogen). Platinum PCR SuperMix High-Fidelity Kit (Invitrogen)
was used for amplification of cDNA according to manufacturer’s
instructions (Invitrogen). The ABI 7700 Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA) was used for analysis. QPCR was
performed as previously described [2]. Gene analysis and the sequences
of the primers used are as previously described [2,17].
Immunoblot Analysis and Immunofluorescence
Western blot analysis was performed as previously described [20]
using the following antibodies: goat anti-ARTN polyclonal antibody
(R&D Systems, Minneapolis, MN), mouse anti-CD24 monoclonal
IgG1 (Santa Cruz Biotechnology, Santa Cruz, CA), and a mAb against
β-actin (Santa Cruz Biotechnology). Confocal laser scanningmicroscopy
was performed as previously described [21] using tetramethyl-rhodamine
B isothiocyanate–phalloidin (Sigma, St Louis, MO).
Apoptosis, Proliferation, and Oncogenicity Assays
A total of 5 × 105 cells per well were seeded in a six-well plate for
the evaluation of apoptosis and nuclear ring formation. Apoptosis was
determined by using Annexin V–FLUOS staining kit (Roche Diagnos-
tics GmbH, Roche Applied Science Nonnenwald, Penzberg, Germany)
following the manufacturer’s instructions. For nuclear ring forma-
tion, cells were fixed for 20 minutes in 4% paraformaldehyde in
phosphate-buffered saline (PBS; pH 7.4) at room temperature and were
stained with the tetramethyl-rhodamine B isothiocyanate–phalloidin
(Sigma) for 45 minutes at room temperature. Ten photos from each
well were obtained, and cells with nuclear ring formation were analyzed
using ImageJ software (version 2.02; National Institutes of Health,
Bethesda, MD). For the determination of total cell number, cells were
seeded in six-well plates at a density of 5 × 104 cells per well in 10%
FBS medium. Cells counts were conducted every 2 days for 14 days.
Entry to the S phase was assayed by measuring the incorporation of
5-bromo-2-deoxyuridine as previously described [2,17]. In vitro cell in-
vasion assays were performed in BD BioCoat Matrigel invasion cham-
bers (BD Biosciences, Bedford, MA) according to the manufacturer’s
instructions as described previously [2,17]. A total of 2.5 × 104 cells
were seeded in serum-free medium in the upper chamber. The lower
chamber contained 10% FBSmedium. After a 48-hour incubation, fil-
ters were washed with PBS, fixed with paraformaldehyde, and stained
with crystal violet, and cells were counted. Other biological assays
such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, anchorage-independent growth (soft agar colony for-
mation and foci formation), and three-dimensional morphogenesis were
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performed as previously described [2,17]. The MTT assay was per-
formed, and half maximal inhibitory concentration (IC50) values were
calculated on the basis of the percentage of treatment over control as
described previously [22].
Flow Cytometry
Cell cycle analysis was performed as previously described [23]. Fluo-
rescence emitted from the propidium iodide–DNA complex was quan-
tified using BD FACSAria Cell Sorter (BD Biosciences, San Jose, CA).
For CD24 expression, cells were harvested and resuspended in PBS/
1% FBS. The antihuman CD24 antibody (BD Pharmingen, San Diego,
CA) was applied according to the manufacturer’s manual. After antibody
binding for 25 minutes at room temperature, cells were rinsed three
times with PBS, and flow cytometry analyses were performed in trip-
licate. As negative controls, cells were stained either with isotype-
matched control antibodies or with no primary antibody.
Xenograft Analyses
RL95-2-vector or RL95-2-ARTN cells (1.5 × 108) were sus-
pended in 100 μl of PBS and were injected subcutaneously into 3-
to 4-week-old BALBc nu/nu mice (Shanghai Slaccas Co, Shanghai,
China). Histological analyses were performed as previously described
[2]. Experiments were performed according to Institutional Animal Care
and Use Committee guidelines (available at http://www.iacuc.org) with
local institutional approval.
EC Tissue Microarray and Immunohistochemistry
EC tissue samples were collected from 45 female patients from the
First Affiliated Hospital of Anhui Medical University (Hefei, Anhui,
China) between 2004 and 2006. All 45 EC cases are endometrioid
adenocarcinoma. The negative internal controls were the stromal cells
of endometrium or smooth muscle cells of the uterus as background.
Positive internal controls were EC samples with an intensity score of
3. Immunohistochemical analysis was performed as previously de-
scribed [2] with polyclonal antibody to human ARTN (Abcam, Ltd,
Cambridge, UK) and mAb against human CD24 (Thermo Fisher
Scientific, Rockford, IL). Method for localization and histoscore of
stained sections were performed as previously described [2].
Statistics
All experiments were performed at least three times. All numerical
data are expressed as mean ± SD from a representative experiment per-
formed in triplicate. Data were analyzed using an unpaired two-tailed
t test or analysis of variance by GraphPad Prism 5 (GraphPad Software,
Inc, La Jolla, CA).
Results
Forced Expression of ARTN in EC Cells Decreased Sensitivity
to Doxorubicin and Paclitaxel
Appreciable differences in cell proliferation were evident by the
forced expression of ARTN in RL95-2 and AN3 cell lines as previously
reported [2]. We therefore determined the IC50 of doxorubicin and
paclitaxel in RL95-2 and AN3 cell lines with forced expression of
ARTN after exposure to doxorubicin or paclitaxel using the MTT via-
bility assay (Figure W1). The IC50 values of doxorubicin and paclitaxel
in RL95-2-ARTN cells were nearly 2-fold and 1.5-fold higher than
those of the RL95-2-vector cells, respectively. The IC50 values of doxo-
rubicin and paclitaxel in AN3-ARTN cells were nearly twofold and
threefold higher than those of the AN3-vector cells, respectively. Con-
cordantly, the IC50 values of doxorubicin and paclitaxel for RL95-2-
siARTN and AN3-siARTN cells were reduced when compared with
RL95-2-sivector and AN3-sivector cells, respectively. The IC50 values
of doxorubicin or paclitaxel in RL95-2 and AN3 cell lines with forced
or depleted expression of ARTN are tabulated (Table 1). IC50 values
of doxorubicin and paclitaxel in control cells (transfected with empty
vector or negative control sequence for siRNA) were not significantly
different when compared with the parental cell lines, RL95-2 and AN3
(Table 1).
To determine the functional consequences of ARTN expression on
the response of EC cells to doxorubicin and paclitaxel, we used the
IC50 relevant for each cell line for further bioassays. Forced expres-
sion of ARTN in RL95-2 cells significantly enhanced their capacity for
anchorage-independent growth when compared with vector control
cells, and on exposure to either doxorubicin or paclitaxel, both RL95-
2-vector and RL95-2-ARTN cells exhibited decreased anchorage-
independent growth. However, the anchorage-independent growth of
RL95-2-ARTN cells decreased significantly less on exposure to doxo-
rubicin and paclitaxel compared with RL95-2-vector cells (Figure 1A).
Depletion of ARTN in RL95-2 cells drastically decreased anchorage-
independent growth on exposure to these drugs when compared with
negative control siRNA control cells (Figure 1A). Doxorubicin and pac-
litaxel not only inhibit cell viability but also independently inhibit in-
vasion of human carcinoma cells [24,25]. RL95-2-ARTN cells also
exhibited increased invasion compared with RL95-2-vector cells [2],
and on exposure to either doxorubicin or paclitaxel, both RL95-2-vector
and RL95-2-ARTN cells exhibited decreased invasion through the
Matrigel. However, invasion of RL95-2-ARTN cells decreased signifi-
cantly less compared with RL95-2-vector cells on exposure to doxo-
rubicin or paclitaxel (Figure 1B). siRNA-mediated depletion of ARTN
in RL95-2 cells further significantly decreased invasion on exposure to
doxorubicin and paclitaxel when compared with respective control cells
treated with doxorubicin and paclitaxel (Figure 1B).
In addition, forced or depleted expression of ARTN in a second EC cell
line, AN3, exhibited similar effects on anchorage-independent capacity
and cell invasion on exposure to doxorubicin or paclitaxel (Figure 1).
Functional Inhibition of ARTN in EC Cells Enhanced the
Efficacy of Doxorubicin and Paclitaxel
Functional inhibition of ARTN by antibodies has been reported to
reduce oncogenicity and invasiveness of EC cells [2]. We therefore
Table 1. IC50 of Doxorubicin (DOX) or Paclitaxel (PTX) on the Viability of RL95-2 and AN3
Cell Lines with Forced or Depleted Expression of ARTN.
Cell Line IC50
DOX (μM) PTX (nM)
RL95-2 Wild-type 6.19 ± 0.17 119.21 ± 7.24
Vector 6.17 ± 0.26 129.00 ± 8.34
ARTN 12.33 ± 0.60 199.90 ± 4.80
sivector 6.16 ± 0.26 125.20 ± 9.03
siARTN 3.27 ± 0.42 72.34 ± 6.23
AN-3 Wild-type 6.23 ± 0.11 96.84 ± 8.27
Vector 6.24 ± 0.22 82.12 ± 6.90
ARTN 12.56 ± 0.36 279.19 ± 15.41
sivector 6.17 ± 0.29 100.10 ± 6.05
siARTN 3.04 ± 0.47 50.05 ± 2.99
Cell viability was measured using the MIT assay after a 72-hour drug exposure period with DOX
or PTX followed by a 24-hour drug-free period as described in Materials and Methods. IC50 values
are presented as mean ± SD of three independent experiments.
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evaluated the effect of ARTN IgY in combination with doxorubicin or
paclitaxel on EC cells. Functional inhibition of ARTN in RL95-2 cells
resulted in increased sensitivity to doxorubicin and paclitaxel up to
40% and 61% in monolayer culture (Figure 1C ), up to 60% and 66%
in soft agar colony formation (Figure 1D), and up to 36% and 68%
during Matrigel invasion (Figure 1E), respectively, when compared with
cells exposed to drug with control IgY alone. Similarly, in AN3 cells, IgY
inhibition of ARTN resulted in increased sensitivity to doxorubicin and
paclitaxel, up to 58% and 39% in monolayer culture (Figure 1C), up to
65% and 50% in soft agar colony formation (Figure 1D), and up to 25%
and 60% during Matrigel invasion (Figure 1E), respectively, when com-
pared with cells exposed to drug with control IgY alone.
Forced Expression of ARTN in RL95-2 Cells Abrogated
Doxorubicin-Induced G2-M Phase Arrest and
Paclitaxel-Induced Apoptosis
In response to DNA damage, cells arrest at G1, intra-S, or G2-M cell
cycle checkpoints to allow for repair or to induce apoptosis [26]. We
therefore used FACS analysis to determine the cell cycle profiles of
RL95-2-vector and RL95-2-ARTN cells treated with various doses of
doxorubicin. Vehicle-treated RL95-2-vector cells were proportionally
distributed in the G0-G1 (55%), S (17%), and G2-M (27%) phases.
Treatment of RL95-2-vector cells with doxorubicin induced a major
shift in the cell cycle from the G0-G1 phase to the G2-M phase; the
G2-M phase peak was elevated at 2 μMdoxorubicin and increased with
Figure 1. ARTN expression in EC cells decreased sensitivity to doxorubicin and paclitaxel. IC50 doses of doxorubicin or paclitaxel against
RL95-2 and AN3 cell lines were used, respectively. (A) Anchorage-independent growth of RL95-2 (left side) and AN3 (right side) cells with
forced or depleted expression of ARTN on exposure to doxorubicin or paclitaxel was evaluated using soft agar colony formation. (B) Cellular
invasionwith RL95-2 (left side) and AN3 (right side) cells with forced or depleted expression of ARTN on exposure to doxorubicin or paclitaxel
was evaluated using transwell assay. (C) Cell viability of RL95-2 and AN3 cells on exposure to doxorubicin or paclitaxel in combination with
anti-ARTN IgY or control IgY was evaluated using MTT assay. (D) Anchorage-independent growth of RL95-2 and AN3 cells on exposure to
doxorubicin or paclitaxel in combinationwith anti-ARTN IgY or control IgYwas evaluated using soft agar colony formation. (E) Cellular invasion
of RL95-2 and AN3 cells on exposure to doxorubicin or paclitaxel in combination with anti-ARTN IgY or control IgY was evaluated using
transwell assay. Columns are mean of triplicate experiments; bars, ±SD. **P < .001, *P < .05.
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increasing concentration of doxorubicin to 12.5 μM, with 92% of the
cells arrested in the G2-M phase. Accordingly, the percentage of RL95-2-
vector cells at the G0-G1 and S phases decreased (Figure 2A). Vehicle-
treated RL95-2-ARTN cells exhibited an altered cell cycle profile
compared with RL95-2-vector cells and were distributed in the G0-G1
(49%), S (35%), andG2-M (15%) phases. Treatment of RL95-2-ARTN
cells with doxorubicin induced a minor shift of the cell cycle from the
G0-G1 phase to the G2-M phase when compared with RL95-2-vector
cells; only 42% of the RL95-2-ARTN cells were arrested in the G2-
M-phase at 12.5 μM doxorubicin, significantly less than RL95-2-
vector cells treated with a similar dose of doxorubicin. Accordingly, the
percentage of RL95-2-ARTN at the G0-G1 and S phases were higher
when compared with RL95-2-vector cells treated with doxorubicin
(Figure 2A).
We also performed FACS analysis to determine the cell cycle profiles
of RL95-2-vector and RL95-2-ARTN cells treated with paclitaxel. Pac-
litaxel induced a major shift from the G0-G1 phase to the S phase; the
S-phase peak was elevated at 25 nM paclitaxel and increased with in-
creasing concentration of paclitaxel to 200 nM, with 65% of the cells
arrested in the S phase. Paclitaxel treatment of RL95-2-vector cells in-
duced apoptosis at 200 nM, with a 26% apoptotic rate. Paclitaxel treat-
ment of RL95-2-ARTN cells also produced a shift from the G0-G1
phase to the S phase and induced apoptosis (Figure 2B). However, pac-
litaxel treatment of RL95-2-ARTN cells produced a less pronounced
shift to the S phase (57% vs 65%) and apoptosis (18% vs 26%) com-
pared with that of RL95-2-vector cells, indicative of a protective effect
of ARTN in paclitaxel-induced apoptosis (Figure 2B).
Forced Expression of ARTN in EC Cells Diminished
the Paclitaxel-Induced Nuclear F-actin Ring Formation
and Apoptosis
Paclitaxel interferes with microtubule depolymerization and results
in stabilized microtubule structures, which disrupt the organization
of F-actin and lead to apoptosis [27,28]. Development of circumferen-
tial actin bundles (also known as nuclear actin ring formation) has been
observed in mammary carcinoma cells after treatment with paclitaxel
[29]. We therefore visualized the F-actin network in RL95-2-vector
and RL95-2-ARTN cells after exposure to paclitaxel (Figure 2C ). In
RL95-2-vector control (vehicle-treated) cells, F-actin was observed as
fine, diffuse, and evenly distributed cytoplasmic filaments. RL95-2-
vector cells treated with paclitaxel exhibited relatively thicker circumfer-
ential F-actin bundles organized around nuclei; the number of cells
with nuclear ring was increased at 25 nM paclitaxel and continued to
increase with increasing concentration of paclitaxel to 200 nM (Fig-
ure 2D). Accordingly, the number of apoptotic cells also increased
with paclitaxel treatment of RL95-2-vector cells (Figure 2E ). RL95-
2-ARTN control (vehicle-treated) cells exhibited actin extensions at
the rim of the cell and diffuse F-actin stress fibers throughout the cell
cytoplasm (Figure 2C). RL95-2-ARTN cells treated with various doses
of paclitaxel exhibited a significantly lower number of cells with nuclear
ring compared with RL95-2-vector cells (Figure 2D). RL95-2-ARTN
cells treated with paclitaxel also exhibited significantly less apoptosis
than RL95-2-vector cells (Figure 2E). We also observed similar results
with forced expression of ARTN in AN3 cells after exposure to pacli-
taxel (Figure W2).
ARTN Specifically Regulated Expression of CD24
We performed microarray analyses of RL95-2 cells with forced
expression of ARTN compared with vector control cells to identify
ARTN-regulated genes in EC and therefore potential mediators of
ARTN-stimulated chemoresistance. Therein, we observed that the ex-
pression of CD24 messenger RNA (mRNA) was increased by approxi-
mately twofold by forced expression of ARTN in RL95-2 cells (data
not shown). To verify this result, we performed luciferase assays using
the 5′ 1.2-kb region of the CD24 gene promoter [19]. The promoter
activity of CD24 was significantly increased by forced expression of
ARTN in RL95-2 cells (Figure 3A). Furthermore, CD24 promoter activ-
ity was suppressed by siRNA-mediated depletion of ARTN expression
in RL95-2 cells (Figure 3A). Forced expression of ARTN in RL95-2 cells
increased levels of CD24 mRNA, as demonstrated using qPCR analyses
(Figure 3B). Furthermore, we confirmed by FACS analysis a higher ex-
pression of CD24 surface protein consequent to the forced expression of
ARTN in RL95-2 cells (Figure 3C). Depletion of ARTN in RL95-2 cells
also decreased CD24 mRNA (Figure 3B). Moreover, a lower expression
of CD24 surface protein was observed consequent to the depletion of
ARTN in RL95-2 cells (Figure 3C ). Similar results for the regulation
of CD24 by ARTN were observed in AN3 cells (Figure 3). We also de-
termined CD24 expression by immunohistochemistry (IHC) in tumors
generated in vivo from RL95-2-vector and RL95-2-ARTN cells [2].
RL95-2-ARTN cell–generated tumors exhibited increased CD24 expres-
sion compared with RL95-2-vector cell–generated tumors (Figure 3D).
We next determined whether ARTN expression correlated with
CD24 expression in EC. Hence, we examined ARTN and CD24
expression by IHC staining in serial histological sections of EC from
45 patients (Figure 3E). In tumors with high ARTN expression (scores
2 and 3) [2], 72% also highly expressed CD24, whereas in tumors with
low ARTN expression (scores 0 and 1), only 38% expressed either low
or high levels of CD24 (Spearman coefficient, ρ = 0.36, P < .016;
Figure 3F ). Hence, CD24 expression in EC is partially correlated with
ARTN expression.
Figure 2. Forced expression of ARTN in RL95-2 cells abrogated doxorubicin-induced G2-M phase arrest and paclitaxel-induced apoptosis.
(A) RL95-2-vector and RL95-2-ARTN cells were treated for 72 hours with doxorubicin (DOX) of the indicated dose and determination of cell
cycle profile by FACS analysis. The cell counts versus PI staining are shown. (B) RL95-2-vector and RL95-2-ARTN cells were treated for
72 hours with paclitaxel (PTX) of the indicated dose and determination of cell cycle profile by FACS analysis. The cell counts versus PI
staining are shown. (C) Confocal microscopic visualization of F-actin network after treatment with the indicated dose of paclitaxel (PTX).
Red arrows indicate the positive nuclear F-actin ring formation. (D) Effect of forced expression of ARTN in RL95-2 cells on paclitaxel-induced
nuclear ring formation. Cells were treated with the indicated dose of PTX and visualized for nuclear ring formation. The figure represents the
average percentage of cells with positive nuclear ring versus total number of cells counted. Columns are mean of triplicate experiments;
bars, ±SD. (E) Effect of forced expression of ARTN in RL95-2 cells on paclitaxel-induced apoptosis. Cells were treated with the indicated
dose of paclitaxel for 72 hours and then assayed using Annexin V–FLUOS staining kit. Points are mean of triplicate experiments; bars, ±SD.
**P < .001, *P < .05.
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Forced Expression of CD24 in EC Cells Stimulated Cellular
Proliferation, Oncogenicity, and Invasion
To determine the functional consequences of CD24 expression in EC
cells, we stably transfected RL95-2 and AN3 cells with an expression
plasmid encoding CD24 cDNA (designated as RL95-2-CD24 and
AN3-CD24) or with the respective empty plasmids as control (desig-
nated as RL95-2-vector and AN3-vector). We also depleted the expres-
sion of CD24 in RL95-2 and AN3 cells using shRNA (designated as
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RL95-2-shCD24 and AN3-shCD24). Control cells were transfected with
respective scrambled controls (designated as RL95-2-vector and AN3-
vector). The expression of CD24 mRNA and surface protein was dem-
onstrated by qPCR and FACS analysis, respectively (Figure 4, A and B).
In monolayer culture, total cell number of RL95-2-CD24 increased
significantly more than the cell number of RL95-2-vector during a
period of 14 days in serum replete medium (Figure 4C ). In addi-
tion, RL95-2-CD24 cells exhibited significantly enhanced cell viability
(RL95-2-vector 100% ± 2.1% vs RL95-2-CD24 172.7% ± 1.6%, P <
.001) compared with RL95-2-vector cells. RL95-2-CD24 cells ex-
hibited significantly increased cell cycle S-phase entry as determined
by 5-bromo-2-deoxyuridine incorporation (43% ± 5.1% vs 30% ±
4.7%, P < .001) compared with RL95-2-vector cells. RL95-2-CD24
cells also exhibited diminished apoptotic cell death compared with
RL95-2-vector cells (12.8% ± 0.8% vs 19.8% ± 3%, P < .05) as a
consequence of serum deprivation. In addition, we used qPCR analy-
sis to examine the effect of forced expression of CD24 on the relative
expression levels of genes involved in cell cycle progression and cell
survival (Table 2). Forced expression of CD24 increased the mRNA
levels of CCND1, Cyclin E1, CDC25A, andCDK2 required for cell cycle
progression and of BCL-2 and BCL2L1, antiapoptotic genes required for
cell survival. In addition, decreased mRNA levels of proapoptotic genes
including TP53 and BAD were observed in RL95-2 cells consequent to
the forced expression of CD24. Forced expression of CD24 in RL95-2
cells also increased levels of TERTmRNA indicative of decreased cellular
senescence and enhanced cell survival [30].
Figure 3. ARTN regulates CD24 expression in EC cells. (A) Effect of ARTN on the activity of the CD24 promoter in RL95-2 and AN3 cell
lines. The luciferase assay was peformed as described in Materials and Methods. (B) Effect of ARTN on the mRNA levels of CD24 in
RL95-2 and AN3 cell lines. QPCR analysis of CD24 in RL95-2-vector/RL95-2-ARTN, RL95-2-sivector/RL95-2-siARTN, AN3-vector/AN3-
ARTN, and AN3-sivector/AN3-siARTN cells. (C) Cells were cultured in serum replete medium for 72 hours. Flow cytometric analysis
was performed with phycoerythrin (PE) antihuman CD24 antibody using the BD FACSAria Cell Sorter. Values in the figure represent
the geometric mean fluorescence of CD24 detected. Black line represents CD24 expression in control cells, and red line represents
CD24 expression with forced or depleted expression of ARTN in RL95-2 and AN3 cell lines, respectively. (D) Representative images of
IHC staining for CD24 expression in RL95-2-vector and RL95-2-ARTN cell-derived xenograft tumors. (E) Representative images of IHC
staining for ARTN and CD24 expression in EC patient tissues. (F) Graphical representation of the Spearman correlation of CD24 expres-
sion with ARTN expression in EC patients. Columns are mean of triplicate experiments; bars, ±SD. **P < .001, *P < .05.
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Figure 4. Forced expression of CD24 stimulates cellular proliferation, oncogenicity, and invasion of EC cells. RL95-2 and AN3 cells were
stably transfected with an expression vector containing CD24 cDNA (designated as RL95-2-CD24 and AN3-CD24). Control cells lines were
transfected with the vector (designated as RL95-2-vector and AN3-vector). CD24 expression was depleted in RL95-2 and AN3 cell line
using shRNA (designated as RL95-2-shCD24 and AN3-shCD24). Control cells lines were transfected with the scrambled shRNA control
vector (designated as RL95-2-shvector and AN3-shvector). (A) QPCR analysis of CD24 expression in RL95-2-vector/RL95-2-CD24, RL95-2-
shvector/RL95-2-shCD24, AN3-vector/AN3-CD24, and AN3-shvector/AN3-shCD24 cells. (B) Cells were cultured in serum replete medium
for 72 hours. To determine CD24 cell surface expression, flow cytometry analysis was performed with PE antihuman CD24 antibody by
use of BD FACSAria Cell Sorter. Values in the figure represent the geometric mean fluorescence of CD24 detected. (C) Total cell number of
RL95-2-vector and RL95-2-CD24 cell lines were assessed in serum replete medium. (D) Anchorage-independent growth of RL95-2-vector
and RL95-2-CD24 cells was evaluated by soft agar colony formation. (E) Cell invasion of RL95-2-vector and RL95-2-CD24 cells was de-
termined by transwell chamber assay. (F) Three-dimensional growth of RL95-2-vector and RL95-2-CD24 cells cultured in growth factor–
reduced Matrigel with serum replete medium. Graph represents the number of colonies produced by RL95-2-vector and RL95-2-CD24 cells
at the indicated period. (G) Foci formation of RL95-2-vector and RL95-2-CD24 cells in serum replete medium. Columns are mean of triplicate
experiments; bars, ±SD. **P < .001, *P < .05.
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Forced expression of CD24 in RL95-2 cells significantly enhanced
anchorage-independent growth as indicated by colony formation in
soft agar (Figure 4D) and foci formation (Figure 4G ). Furthermore,
qPCR analysis comparing RL95-2-vector and RL95-2-CD24 cell lines
demonstrated increased mRNA levels of various signal transduction
molecules and transcription factors (Table 2). Of note, mRNA levels
for AKT1, JUN, ETS2, ERBB2, TWIST1, and MYC, previously dem-
onstrated to be associated with increased oncogenicity of EC cells
[2,31–33], were increased by forced expression of CD24 in RL95-2
cells. Three-dimensional structures were also generated by plating
RL95-2-vector and RL95-2-CD24 cells as single cells in Matrigel.
RL95-2-vector colonies appeared well defined with regular spheroid
morphology. In contrast, RL95-2-CD24 colonies exhibited markedly
increased sizes of the individual colony, and colonies were of irregular
morphology (Figure 4F ). Moreover, RL95-2-CD24 cells produced a
significantly increased total number of colonies compared with RL95-
2-vector cells (Figure 4F).
RL95-2 cells with forced expression of CD24 exhibited significantly in-
creased invasion through Matrigel (Figure 4E). In addition, the mRNA
levels of invasion- and metastasis-promoting genes, MET, PLAUR, and
PI5/SERPINB5, were significantly increased in RL95-2-CD24 cells rela-
tive to RL95-2-vector cells (Table 2). Also, in accord with themorphologi-
cal changes observed with forced expression of CD24, qPCR analysis
demonstrated markedly increased mRNA levels of the mesenchymal
marker, vimentin, in RL95-2-CD24 cells relative to RL95-2-vector cells
(Table 2). Thus, forced expression of CD24 in EC cells produced an
aggressive cellular phenotype with increased invasion.
In addition, we examined the effect of forced expression of CD24
on a second EC cell line, AN3. Forced expression of CD24 in AN3
cells was verified by qPCR and FACS analysis (Figure 4, A and B).
Forced expression of CD24 in AN3 cells resulted in increased cell via-
bility, anchorage-independent growth, and cell invasion (Figure W3).
In addition, similar directional changes in the expression of genes in-
volved in increased oncogenicity were observed after forced expression
of CD24 in AN3 cells (Table W1).
Forced Expression of CD24 in EC Cells Decreased Sensitivity
to Doxorubicin and Paclitaxel
EC cells with forced expression of CD24 exhibited increased viability
compared with vector control cells, and on exposure to either doxo-
rubicin or paclitaxel, both RL95-2-vector and RL95-2-CD24 cells
exhibited decreased viability. However, RL95-2-CD24 cells exhib-
ited enhanced cell viability when compared with RL95-2-vector cells
on exposure to doxorubicin and paclitaxel (Figure 5A). Accordingly,
shRNA-mediated depletion of CD24 in RL95-2 cells drastically de-
creased cell viability when compared with respective control cells on ex-
posure to doxorubicin and paclitaxel (Figure 5B). Furthermore, forced
expression of CD24 in RL95-2 cells significantly enhanced their ca-
pacity for anchorage-independent growth when compared with vector
control cells, and on exposure to either doxorubicin or paclitaxel,
both RL95-2-vector and RL95-2-CD24 cells decreased their capacity
for anchorage-independent growth (Figure 5C ). However, anchorage-
independent growth of RL95-2-CD24 cells was inhibited significantly
less compared with RL95-2-vector cells on exposure to doxorubicin
and paclitaxel (Figure 5C). Depletion of CD24 in RL95-2 cells drasti-
cally decreased their capacity for anchorage-independent growth on
exposure to doxorubicin and paclitaxel when compared with respective
control cells (Figure 5D). RL95-2-CD24 cells exhibited increased in-
vasion compared with RL95-2-vector cells, and on exposure to either
doxorubicin or paclitaxel, both RL95-2-vector and RL95-2-CD24 cells
exhibited decreased invasion. However, RL95-2-CD24 cells exhibited
no change in invasive capacity on exposure to doxorubicin, whereas
RL95-2-CD24 cell invasion decreased significantly less on exposure
to paclitaxel when compared with RL95-2-vector cells (Figure 5E). De-
pleted expression of CD24 in RL95-2 cells resulted in further signifi-
cant decrease in invasion on exposure to these drugs individually when
compared with respective control cells (Figure 5F).
In addition, forced or depleted expression of CD24 in AN3 cells ex-
hibited similar directional effects on cell viability, anchorage-independent
growth, and invasion on exposure to doxorubicin and paclitaxel when
compared with vector-transfected control cells (Figure W3).
Table 2. qPCR Analysis of the Effect of Forced Expression of CD24 on mRNA Levels of Several
Key Genes Functionally Involved in Oncogenicity and Neoplastic Progression of EC Cells*.
Functional Gene Grouping Gene Fold Change† P
Cell cycle control and DNA damage repair CCND1 3.92 1.36e−06
ATM 2.14 2.71e−02
BRCA1 2.26 6.49e−06
Cyclin E1 1.90 2.19e−05
CDC25A 3.09 2.10e−03
CDK2 3.13 2.94e−02
CDKN1A 1.75 1.86e−02
CDKN2A 1.53 2.81e−02
CHEK2 1.72 6.10e−04
E2F1 2.48 4.36e−04
CDKN1B −1.31 9.19e−04
RB1 2.03 2.81e−05
Apoptosis and cell senescence S100A4 1.79 4.46e−05
TP53 −1.84 1.03e−04
APAF1 2.20 3.16e−04
BAD −3.20 5.91e−03
BAX 2.19 1.28e−04
BCL2 3.64 2.35e−05
BCL2L1 1.86 6.11e−03
CASP7 2.11 1.44e−06
HTATIP2 −7.28 1.43e−02
TERT 2.89 3.39e−02
TNFRSF1A 2.91 1.98e−03
TNFRSF10B 2.06 2.57e−04
Signal transduction molecules and transcription factors AKT1 2.27 6.11e−06
ERBB2 3.61 4.86e−03
ETS2 2.16 2.80e−05
FOS 1.86 2.54e−02
JUN 2.03 4.43e−04
MAP2K1 2.05 1.19e−02
MYC 2.19 8.43e−03
NFKB1 2.34 1.16e−04
NFKBIA 2.04 1.60e−04
PIK3R1 2.77 6.79e−03
RAF1 2.75 5.59e−03
SNCG 1.81 1.24e−05
TWIST1 2.46 2.31e−02
Invasion and metastasis MET 2.06 7.36e−06
MTA1 2.38 2.50e−02
MTA2 2.28 4.26e−03
NME1 1.69 4.56e−02
PLAU −2.83 8.21e−04
PLAUR 1.85 2.41e−03
SERPINB5 2.08 1.59e−02
Cell remodeling VIM 35.40 1.57e−02
OCLN −2.85 4.23e−04
FN1 1.93 2.17e−02
Positive and negative fold changes indicate an increase or a decrease in mRNA levels respectively.
A list of the genes analyzed by real-time PCR and the primer sequences used are previously de-
scribed [2].
*Results are presented as a fold change in mRNA levels in RL95-2-CD24 cells relative to RL95-2-
vector cells.
†Fold change values are representative of three independent experiments of mRNA samples.
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CD24 Expression Is Essential for ARTN-Stimulated Resistance
to Doxorubicin and Paclitaxel in EC Cells
We next evaluated the effect of doxorubicin and paclitaxel on the
anchorage-independent capacity and invasion of RL95-2-vector/
RL95-2-ARTN and RL95-2-sivector/RL95-2-siARTN cells with de-
pleted expression of CD24. As previously described, RL95-2-ARTN
cells exhibited significantly increased capacity for anchorage-independent
growth and invasion compared with RL95-2-vector cells. Depletion
of CD24 reduced both basal and ARTN-stimulated anchorage-
independent growth and invasion (Figure 6, A and C ). Depletion of
CD24 also eliminated or largely abrogated the stimulatory effect of
ARTN on anchorage-independent growth and invasion in the presence
of doxorubicin and paclitaxel. Combined depletion of ARTN and
CD24 expression in RL95-2 cells drastically decreased the capacity for
anchorage-independent growth and invasion on exposure to doxo-
rubicin and paclitaxel when compared with their respective control cells
or individual depletion of either ARTN or CD24 alone (Figure 6, B
and D). In addition, AN3-vector/AN3-ARTN cells with depleted ex-
pression of CD24 exhibited similar directional effects on anchorage-
independent growth and invasion on exposure to doxorubicin and
paclitaxel when compared with vector-transfected control cells (Fig-
ure W4). Thus, depleted expression of CD24 in EC cells abolished
ARTN-stimulated resistance to doxorubicin and paclitaxel.
Discussion
Advanced and recurrent EC present a difficult therapeutic challenge for
clinicians. The mainstay treatment of recurrent and metastatic EC re-
mains systemic therapy in the form of hormonal therapy (progestins,
tamoxifen combined with progestins, and aromatase inhibitors) and/or
cytotoxic chemotherapy [16]. Unfortunately, new approaches for the
treatment of patients with advanced and recurrent EC have been slow
to materialize. Treatment with single-agent doxorubicin or paclitaxel
results in median overall survival intervals of less than 10 months
[1,16]. Even when given as combined therapy, median overall survival
after administration of doxorubicin and paclitaxel is marginally en-
hanced to 13.6 months [34]. In this report, we observed that functional
inhibition of ARTN with antibody, when combined with doxorubicin
or paclitaxel, resulted in enhanced reductions in oncogenicity and in-
vasiveness of EC cell lines. Therefore, an inhibitor such as a mAb tar-
geting ARTN may be a viable adjuvant therapy in EC.
Herein, we demonstrated that CD24 enhanced the oncogenicity and
invasion of EC cells. Elevated levels of CD24 have also been reported to
be associated with the progression of EC and indicate a worse prognosis
[5,35]. Several studies have also reported the association of CD24 ex-
pression with a more aggressive phenotype and poor prognosis in other
types of carcinomas, such as mammary, prostate, ovarian, and pancreatic
carcinomas [6–9,36]. Transient depletion of CD24 expression or mAb
inhibition of CD24 resulted in reduced oncogenicity and xenograft
growth of various human carcinoma cell lines [14,15]. CD24 therefore
exerts similar functional effects in EC and other carcinoma cells as ARTN
[2,4]. It should be noted, however, that ARTN is amore potent promoter
of oncogenicity and invasion than CD24, at least in the cell lines used
herein. ARTN, therefore, will presumably use other CD24-independent
pathways to exert its oncogenic and invasive effects in EC cells.
Herein, we demonstrated that CD24 expression mediated ARTN-
induced resistance to doxorubicin and paclitaxel in EC cells. The role
of CD24 in chemosensitivity was first suggested when high expres-
sion of CD24 was reported to be associated with tamoxifen-resistant
Figure 5. Forced expression of CD24 in EC cells decreased sensitivity to doxorubicin and paclitaxel. (A and B) Cell viability of RL95-2 cells
with forced or depleted expression of CD24 on exposure to doxorubicin and paclitaxel was evaluated using the MTT assay. (C and D)
Anchorage-independent growth of RL95-2 cells with forced or depleted expression of CD24 on exposure to doxorubicin and paclitaxel
was evaluated using soft agar colony formation. (E and F) Cellular invasion of RL95-2 cells with forced or depleted expression of CD24
on exposure to doxorubicin and paclitaxel was evaluated using transwell assay. Columns are mean of triplicate experiments; bars, ±SD.
**P < .001, *P < .05.
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ductal mammary carcinoma patients [37]. Also, higher levels of CD24
surface protein were observed in a Hoechst 33342 side population
of stem cell–like carcinoma cells from NXS2 murine neuroblastoma
cells, which exhibit increased resistance to doxorubicin [38]. In human
pancreatic carcinoma stem cells, gemcitabine-resistant cells express in-
creased CD24 surface protein along with CD44 and epithelial-specific
antigen, the increased expression of which is associated with the car-
cinoma stem cell population [39]. Furthermore, primary pancreatic
carcinoma xenografts treated with ionizing radiation and the chemother-
apeutic agent gemcitabine resulted in the enrichment of the CD44-,
CD24-, and epithelial-specific antigen–positive cell population [39]. In
this regard, it is interesting that ARTN has recently been identified as
an embryonic stem cell factor [40]. Gene expression profiles of aggressive
carcinoma correlate with gene expression profiles of embryonic stem cells
[41], and ARTNmay therefore influence chemosensitivity of EC cells by
modulating cancer stem cell activity. In contrast, mammary carcinoma
stem cells with low or negative expression of CD24 are associated with
increased resistance of cells to gemcitabine, paclitaxel, and 5-fluorouracil
[42], suggestive of CD24 tissue specificity. In any case, we have demon-
strated that CD24mediates ARTN-stimulated resistance to doxorubicin
and paclitaxel in EC cells. It is possible that CD24 is an intermediate in
ARTN-stimulated gene expression required for the effects of ARTN in
EC described herein. Indeed, both ARTN [2] and CD24 stimulated the
expression of genes such as CCND1, BCL2, AKT1, TWIST1, and VIM
and decreased BAD and PLAUmRNA in RL95-2 cells. It remains to be
determined whether ARTN stimulates other oncogenic pathways in EC
independent of CD24.
In summary, functional inhibition of ARTN in EC cells increased
the sensitivity to doxorubicin and paclitaxel. Therefore, development
of function-inhibiting antibodies to target ARTN is a viable adjuvant
therapeutic approach to improve the response of EC to specific chemo-
therapeutic agents.
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Figure W1. Cell viability of EC cells with forced or depleted expression of ARTN on exposure to doxorubicin and paclitaxel. Cell viability
of RL95-2-vector/RL95-2-ARTN, RL95-2-sivector/RL95-2-siARTN, AN3-vector/AN3-ARTN, and AN3-sivector/AN3-siARTN cells exposed to
various doses of doxorubicin or paclitaxel. Cells were cultured in 96-well plates in the absence or presence of the indicated concentra-
tion of paclitaxel or doxorubicin for 72 hours followed by a 24-hour untreated period. Cell viability was then determined by using the MTT
assay as described in Materials and Methods. Points are mean of triplicate experiments; bar, ±SD.
Figure W2. Forced expression of ARTN in AN3 cells abrogated paclitaxel-induced F-actin depolymerization and apoptosis. (A) Confocal
microscopic visualization of the F-actin network after PTX treatment. Red arrows represent positive nuclear F-actin ring formation. (B)
Effect of forced expression of ARTN in AN3 cells on paclitaxel-induced nuclear ring formation. Cells were treated with the indicated dose
of PTX and visualized for nuclear ring formation. The figure represents the average percentage of cells with positive nuclear ring versus
total number of cells counted. Columns are mean of triplicate experiments; bars, ±SD. (C) Effect of forced expression of ARTN in AN3
cells on paclitaxel-induced apoptosis in AN3 cells. Cells were treated with the indicated dose of paclitaxel for 72 hours and then assayed
using the Annexin V–FLUOS staining kit. Points are mean of triplicate experiments; bars, ±SD. **P < .001, *P < .05.
Figure W3. Forced expression of CD24 in EC cells decreased sensitivity to doxorubicin and paclitaxel. (A and B) Cell viability of AN3 cells
with forced or depleted expression of CD24 on exposure to doxorubicin and paclitaxel was evaluated using the MTT assay. (C and D)
Anchorage-independent growth of AN3 cells with forced or depleted expression of CD24 on exposure to doxorubicin and paclitaxel
was evaluated using soft agar colony formation. (E and F) Cellular invasion of AN3 cells with forced or depleted expression of CD24
on exposure to doxorubicin and paclitaxel was evaluated using transwell assay. Columns are mean of triplicate experiments; bars, ±SD.
**P < .001, *P < .05.
Table W1. qPCR Analysis of the Effect of Forced Expression of CD24 on mRNA Levels of Several
Key Genes Functionally Involved in Oncogenicity and Neoplastic Progression of AN3 Cells*.
Functional Gene Grouping Gene Fold Change† P
Cell cycle control and DNA damage repair CCND1 2.70 8.06e−03
ATM 2.67 2.53e−04
BRCA1 2.62 1.19e−04
Cyclin E1 1.25 1.46e−05
CDC25A 3.17 1.81e−02
CDK2 3.55 9.41e−06
CDK4 2.29 3.98e−04
CDKN1A 2.56 1.15e−04
CDKN2A 1.49 1.64e−02
CHEK2 1.96 6.84e−06
E2F1 2.93 4.94e−03
CDKN1B 1.65 1.65e−06
RB1 1.57 1.08e−05
Apoptosis and cell senescence S100A4 1.82 4.06e−05
TP53 −4.11 1.58e−04
APAF1 1.33 4.34e−04
BAD −3.86 1.93e−02
BAX 1.06 5.57e−05
BCL2 6.42 2.96e−05
BCL2L1 2.67 1.57e−05
CASP7 1.76 6.91e−06
HTATIP2 −5.24 3.11e−03
TERT 2.18 6.97e−03
TNFRSF1A 4.00 2.39e−05
TNFRSF10B 2.97 1.52e−04
TNFRSF25 2.19 6.91e−03
Signal transduction molecules and transcription factors AKT1 2.17 5.33e−07
ERBB2 2.28 1.59e−04
ETS2 1.97 9.38e−03
FOS 4.55 5.91e−05
JUN 5.89 7.55e−05
MAP2K1 2.79 8.94e−05
MYC 1.36 5.35e−05
NFKB1 2.09 4.85e−04
NFKBIA 1.82 8.95e−06
PIK3R1 2.25 1.04e−02
RAF1 2.12 1.95e−02
SNCG 1.11 2.55e−02
TWIST1 3.51 1.64e−03
Invasion and metastasis MET 2.21 4.28e−02
MTA1 2.23 4.06e−07
MTA2 1.93 5.33e−06
NME1 2.02 2.13e−03
PLAU 1.89 9.44e−03
PLAUR 2.65 4.44e−03
SERPINB5 1.40 1.74e−02
Cell remodeling VIM 6.33 2.43e−04
OCLN 1.67 1.86e−03
FN1 −19.70 9.14e−03
Positive and negative fold changes indicate an increase or a decrease in mRNA levels respectively.
A list of the genes analyzed by real-time PCR and the primer sequences used are previously de-
scribed [2].
*Results are presented as a fold change in mRNA levels in AN3-CD24 cells relative to AN3-
vector cells.
†Fold change values are representative of three independent experiments of mRNA samples.
Figure W4. CD24 expression mediates ARTN-induced resistance to doxorubicin and paclitaxel in AN3 cells. (A) Anchorage-independent
growth of forced expression of ARTN with AN3 cells with depleted expression of CD24 on exposure to doxorubicin and paclitaxel was
evaluated using soft agar colony formation. (B) Cellular invasion of forced expression of ARTN with AN3 cells with depleted expression
of CD24 on exposure to doxorubicin and paclitaxel was evaluated using transwell assay. Columns are mean of triplicate experiments;
bars, ±SD. **P < .001, *P < .05.
